| Specification | Details |
|---|---|
| Composition | Glimepiride IP 1 mg + Pioglitazone Hydrochloride IP 15 mg + Metformin Hydrochloride IP 500 mg (Bilayered) |
| Dosage Form | Tablet |
| Packing Size | 20x1x10 |
| Packing Type | Blister |
PYOSTAL GM 1 is a powerful oral anti-diabetic formulation combining Glimepiride, Pioglitazone, and Metformin Hydrochloride in a convenient bilayered tablet. It is specially developed for the management of Type 2 Diabetes Mellitus (T2DM) in adults whose blood sugar levels are not adequately controlled by diet, exercise, or monotherapy.
The unique triple-drug combination offers a multi-targeted approach by addressing three critical defects of Type 2 Diabetes:
Reduced insulin secretion
Insulin resistance
Excess hepatic glucose production
By simultaneously targeting these pathways, PYOSTAL GM 1 helps patients achieve effective glycemic control and reduces the long-term risks associated with uncontrolled diabetes.
Belongs to the sulfonylurea class.
Stimulates pancreatic beta cells to release more insulin.
Controls postprandial blood glucose spikes.
Enhances glucose utilization in peripheral tissues.
Belongs to the thiazolidinedione (TZD) class.
Improves insulin sensitivity in muscles and adipose tissues.
Reduces insulin resistance without increasing pancreatic insulin secretion.
Helps improve lipid metabolism and supports cardiovascular health.
A first-line biguanide therapy for Type 2 Diabetes.
Decreases glucose production in the liver.
Improves glucose uptake in peripheral tissues.
Reduces intestinal absorption of glucose.
Provides long-term glycemic stability with minimal risk of hypoglycemia.
The combined action of Glimepiride, Pioglitazone, and Metformin ensures comprehensive diabetes management:
Glimepiride: Enhances insulin secretion from pancreatic beta cells.
Pioglitazone: Reduces insulin resistance, enabling efficient glucose uptake.
Metformin: Reduces hepatic glucose output and lowers fasting glucose levels.
This triple-action mechanism effectively controls fasting blood sugar (FBS), postprandial glucose (PPG), and HbA1c levels.
Triple therapy in a single bilayered tablet for convenience.
Provides effective glycemic control in patients not responding to dual therapy.
Significantly reduces HbA1c levels and maintains stable glucose levels.
Lowers the risk of diabetes-related complications like neuropathy, nephropathy, and retinopathy.
Improves insulin sensitivity and overall metabolic health.
Enhances patient compliance by reducing pill burden.
PYOSTAL GM 1 is indicated for:
Type 2 Diabetes Mellitus patients uncontrolled on monotherapy or dual therapy.
Adults requiring combination treatment for better glycemic management.
Patients with risk of developing chronic diabetes complications.
The dosage should be individualized and prescribed by a physician.
Typically taken with meals to reduce gastrointestinal side effects.
Regular monitoring of blood sugar, HbA1c, renal and liver functions is recommended.
Not intended for Type 1 Diabetes Mellitus or Diabetic Ketoacidosis (DKA).
Should be used cautiously in patients with renal or hepatic impairment.
Pioglitazone may cause fluid retention; not suitable for those with congestive heart failure.
Monitor for hypoglycemia, especially when combined with other anti-diabetic medications.
Avoid alcohol consumption to reduce the risk of lactic acidosis associated with Metformin.
Use during pregnancy and lactation only under medical advice.
Commonly reported side effects include:
Hypoglycemia (low blood sugar)
Nausea, vomiting, diarrhea, or abdominal discomfort
Weight gain (due to Pioglitazone)
Edema (fluid retention)
Headache, dizziness, or fatigue
Most side effects are mild and manageable. Patients should consult their doctor if any symptoms persist or worsen.
PYOSTAL GM 1 may interact with:
Other oral anti-diabetic drugs or insulin (increasing hypoglycemia risk).
Antihypertensives and diuretics.
Corticosteroids, thyroid medications, or anticoagulants.
Patients must inform their physician about all ongoing medications before starting PYOSTAL GM 1.
Store in a cool, dry place away from moisture and direct sunlight.
Keep out of reach of children.
Do not consume if the tablet has expired or is damaged.
Combines three proven anti-diabetic medicines in one tablet.
Convenient bilayered design ensures proper release and absorption.
Targets multiple defects in diabetes for better long-term outcomes.
Improves adherence by minimizing the number of daily medications.
Manufactured under strict quality standards for safety and efficacy.
PYOSTAL GM 1 (Glimepiride 1 mg + Pioglitazone 15 mg + Metformin Hydrochloride 500 mg) is an advanced triple therapy solution for patients with Type 2 Diabetes Mellitus who require multi-targeted treatment. Its unique formulation helps manage blood sugar effectively by stimulating insulin release, enhancing insulin sensitivity, and reducing liver glucose production.
With its comprehensive mechanism of action, proven safety, and effective results, PYOSTAL GM 1 plays an essential role in reducing the risk of diabetes complications and improving overall quality of life.
When used under proper medical supervision along with diet and exercise, it ensures stable and long-term control of blood glucose levels in diabetic patients.
